PURPOSE: Activation of the MDR1 upstream promoter (USP) has been described previously in four lymphoblastic leukemia patients, where it is the major MDR1 promoter associated with P-glycoprotein overexpression. We asked whether MDR1 USP-derived transcripts were also present in breast carcinoma and assessed their potential as a biomarker. EXPERIMENTAL DESIGN: We developed a sensitive method for detecting transcripts derived from the MDR1 USP and used it to identify MDR1 USP-derived transcripts in cell model systems, in 61 breast carcinoma biopsies of the primary tumor, and in isolated malignant epithelial cells both from the primary tumor and from the associated invaded lymph nodes. RESULTS: The MDR1 USP was not active in several independent leukemic and breast cancer cell lines or nucleated peripheral blood cells (n = 9). However, transcripts derived from the MDR1 USP were detected in some drug-resistant cell lines and a high proportion of primary breast tumors (71.6%; n = 61), whereas they were present at low frequency in normal breast tissue (10%; n = 10). Activation of MDR1 USP was not due to chromosomal amplifications or rearrangements at the MDR1 locus. Transcription from the MDR1 USP correlated with metastatic node invasion [N = 0-3 versus N > 3 (N = number of lymph nodes invaded); Fisher's exact test, P = 0.011] and was detected in malignant epithelial cells from the primary tumor and those that metastasized to the lymph nodes. CONCLUSIONS: MDR1 USP activation is a surrogate marker for breast carcinoma progression and can be used as a marker to study breast cancer susceptibility.
PURPOSE: Activation of the MDR1 upstream promoter (USP) has been described previously in four lymphoblastic leukemiapatients, where it is the major MDR1 promoter associated with P-glycoprotein overexpression. We asked whether MDR1 USP-derived transcripts were also present in breast carcinoma and assessed their potential as a biomarker. EXPERIMENTAL DESIGN: We developed a sensitive method for detecting transcripts derived from the MDR1 USP and used it to identify MDR1 USP-derived transcripts in cell model systems, in 61 breast carcinoma biopsies of the primary tumor, and in isolated malignant epithelial cells both from the primary tumor and from the associated invaded lymph nodes. RESULTS: The MDR1 USP was not active in several independent leukemic and breast cancer cell lines or nucleated peripheral blood cells (n = 9). However, transcripts derived from the MDR1 USP were detected in some drug-resistant cell lines and a high proportion of primary breast tumors (71.6%; n = 61), whereas they were present at low frequency in normal breast tissue (10%; n = 10). Activation of MDR1 USP was not due to chromosomal amplifications or rearrangements at the MDR1 locus. Transcription from the MDR1 USP correlated with metastatic node invasion [N = 0-3 versus N > 3 (N = number of lymph nodes invaded); Fisher's exact test, P = 0.011] and was detected in malignant epithelial cells from the primary tumor and those that metastasized to the lymph nodes. CONCLUSIONS:MDR1 USP activation is a surrogate marker for breast carcinoma progression and can be used as a marker to study breast cancer susceptibility.
Authors: Emelyne Dejeux; Jo Anders Rønneberg; Hiroko Solvang; Ida Bukholm; Stephanie Geisler; Turid Aas; Ivo G Gut; Anne-Lise Børresen-Dale; Per Eystein Lønning; Vessela N Kristensen; Jörg Tost Journal: Mol Cancer Date: 2010-03-25 Impact factor: 27.401
Authors: Trinidad Mata Balaguer; Angeles Gómez-Martínez; Pilar García-Morales; Javier Lacueva; Rafael Calpena; Lourdes Rocamora Reverte; Natividad Lopez Riquelme; Isabel Martinez-Lacaci; José A Ferragut; Miguel Saceda Journal: BMC Mol Biol Date: 2012-07-30 Impact factor: 2.946
Authors: Melanie Spitzwieser; Christine Pirker; Bettina Koblmüller; Georg Pfeiler; Stefan Hacker; Walter Berger; Petra Heffeter; Margit Cichna-Markl Journal: Oncotarget Date: 2016-11-08